Erasca Announces $150M Common Stock Offering to Fund R&D and Operations
ERAS has more than doubled off its 52-week low of $1.01 on elevated volume (1.9× avg).
Summary
Erasca, Inc. filed a prospectus supplement for a $150 million common stock offering, with an option for underwriters to purchase an additional $22.5 million, to fund its research and development and general corporate purposes.
Key Events · Financing and Capital Events · ERAS
-
Common Stock Offering Announced
Erasca, Inc. is offering $150 million of its common stock to fund research and development, other development programs, and for working capital and general corporate purposes.
-
Underwriters' Option to Purchase Additional Shares
The underwriters have been granted an option to purchase up to an additional $22.5 million of common stock within 30 days.
-
Significant Capital Raise for Clinical-Stage Biotech
This offering represents a substantial capital infusion for the clinical-stage precision oncology company, crucial for advancing its pipeline of RAS/MAPK pathway-driven cancer therapies.
-
Potential for Share Dilution
The offering is expected to result in immediate and substantial dilution for existing shareholders, as noted in the risk factors.
Analysis · ERAS · Life Sciences
This substantial capital raise is critical for Erasca, a clinical-stage precision oncology company, to advance its RAS/MAPK pathway-driven cancer therapies. While the offering will result in significant dilution for existing shareholders, it provides essential funding for ongoing research and development programs and extends the company's operational runway. The ability to raise $150 million, with a potential for $172.5 million, underscores the market's interest in the company's pipeline, despite the dilutive impact.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ERAS was trading at $8.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $1.01 to $10.42. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.